Rob Abbott

Rob Abbott, CEO of ISPOR and leader in health policy and HEOR, explains why health economics and outcomes research matters for early-stage drug developers. Short takes cover starting HEOR early, burden-of-disease and payer landscape studies, AI and real-world evidence, and the power of patient-centered research to shape trials, pricing, and market access.